Skip to content
Open access

Allosteric modulator of dopamine transporter inhibits cocaine-induced behaviors in rats.

Oct 2026 · Journal of Pharmacology and Experimental Therapeutics · Vol 393 11, pp. 105044 · 0 citations · 50 references
Medicine

Abstract

Psychostimulant use disorders, particularly cocaine use disorder, is marked by compulsive drug seeking and high relapse rates. Cocaine blocks the dopamine transporter (DAT), preventing dopamine (DA) reuptake, leading to elevated DA signaling-a key driver of its addictive properties. Although behavioral interventions such as contingency management have demonstrated efficacy in treating stimulant use disorders, their long-term effectiveness and accessibility remain limited, and no US Food and Drug Administration-approved pharmacotherapy for psychostimulant use disorder currently exists, highlighting the need for novel treatment options. We investigated the therapeutic potential of KM822, a novel allosteric DAT modulator that binds to a distinct domain different from the cocaine/DA binding site. When infused into the nucleus accumbens, KM822 significantly attenuated cocaine-induced hyperlocomotion of an intracranial dose of 25 μg cocaine, with no significant effect observed at higher cocaine doses tested. To assess the impact of KM822 on cocaine's rewarding properties, we used the conditioned place preference (CPP) test. KM822 pretreatment during conditioning successfully blocked the development of cocaine-induced CPP. To model relapse, we evaluated cocaine-primed reinstatement in the CPP assay and found that KM822 pretreatment before cocaine priming effectively blocked reinstatement behavior. Importantly, KM822 alone did not produce preference in the CPP test, suggesting that KM822 has low abuse potential. At the protein level, KM822 alone did not significantly alter c-Fos expression, a marker of neuronal activation, but attenuated cocaine-induced c-Fos expression. Together, these findings demonstrate that KM822 can inhibit cocaine-related behaviors and neural responses and serve as a proof of concept for the therapeutic potential of allosterically targeting DAT. SIGNIFICANCE STATEMENT: This project provides proof of concept that targeting the dopamine transporter allosteric site with modulators such as KM822 offers a promising strategy for developing pharmacotherapies for psychostimulant use disorder, especially cocaine use disorder.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.